

## Supporting Information (SI)

# The Influence of Stepwise P-Oxidation on the Coordination and Redox Behavior of W-bisphosalkyne Complex Ligands

Kai Helmdach, Alexander Villinger and Wolfram W. Seidel\*

Institut für Chemie, Universität Rostock,

Albert-Einstein-Straße 3a, 18059 Rostock, Germany

### 1. Content

2.	Crystallographic Details.....	2
3.	Crystal Structure of 1S.....	4
4.	Crystal Structure of 2OO .....	4
5.	Crystal Structure of 4 .....	5
6.	Orbital Interactions in d <sup>4</sup> Alkyne Carbonyl Complexes .....	5
7.	Cyclic Voltammetry .....	6
8.	Stoichiometric Oxidation of 5-PF <sub>6</sub> .....	7
9.	NMR Spectra .....	8
10.	DFT Calculations.....	23
11.	References.....	25

## 2. Crystallographic Details


**Table S1.** Crystallographic details for **1O**, **1S**, **2O**, **2OO** and **2SS**.

	<b>1O</b>	<b>1S</b>	<b>2O</b>	<b>2OO</b>	<b>2SS</b>
empirical formula	$C_{33}H_{39}BIN_6O_2P$ $W \cdot C_5H_{12}$	$C_{33}H_{39}BIN_6OPS$ $W \cdot 1.5 CH_2Cl_2$	$0.9[C_{45}H_{48}BIN_6$ $O_2P_2W] \cdot$ $0.1[C_{45}H_{48}BBrN_6$ $O_2P_2W \cdot CH_2Cl_2]$	$C_{45}H_{48}BIN_6O_3$ $P_2W \cdot CHCl_3$	$C_{45}H_{48}BIN_6OP_2$ $S_2W \cdot CH_2Cl_2$
$M_w / g \cdot mol^{-1}$	976.38	1047.68	1091.61	1223.76	1221.44
colour, habit	green, block	green, block	green, plate	orange, block	red, block
crystal system	orthorhombic	triclinic	monoclinic	triclinic	monoclinic
space group	$Pca2_1$	$P-1$	$P2_1/n$	$P-1$	$P2_1/c$
$a / \text{\AA}$	17.3399(9)	9.7681(6)	10.9974(6)	11.0779(3)	12.9921(16)
$b / \text{\AA}$	10.3826(6)	13.5347(9)	18.5870(11)	11.7986(3)	18.476(2)
$c / \text{\AA}$	21.7550(12)	15.6453(9)	21.9383(13)	19.9114(5)	21.765(3)
$\alpha / {}^\circ$	90	99.294(3)	90	88.563(1)	90
$\beta / {}^\circ$	90	91.660(3)	98.135(2)	81.797(1)	96.020(7)
$\gamma / {}^\circ$	90	105.648(3)	90	70.936(1)	90
$V / \text{\AA}^3$	3916.6(4)	1959.9(2)	4439.3(4)	2433.95(11)	5195.8(11)
Z	4	2	4	2	4
$\rho_{calcd.} / g \cdot cm^{-3}$	1.656	1.775	1.633	1.670	1.561
$\mu / mm^{-1}$	3.819	4.070	3.453	3.284	3.101
$\lambda_{MoK\alpha} / \text{\AA}$	0.71073	0.71073	0.71073	0.71073	0.71073
T / K	123(2)	123(2)	123(2)	123(2)	123(2)
collected refl.	63826	65084	182355	78855	147369
unique refl.	14011	14191	14760	17534	18777
refl. $I > 2\sigma(I)$	12168	11988	11850	15092	16996
$R_{int}$	0.0494	0.0506	0.0786	0.0324	0.0411
parameters/restraints	418/5	489/3	576/36	593/24	595/61
$R_1 [I > 2\sigma(I)]$	0.0264	0.0344	0.0394	0.0382	0.0254
wR <sub>2</sub> (all data)	0.0595	0.0667	0.0745	0.0880	0.0632
GooF	0.912	1.044	1.027	1.046	1.018
resid. density [ $e \text{\AA}^{-3}$ ]	0.981/-1.107	3.437/-1.880	1.427/-1.944	2.223/-3.238	2.283/-1.547
CCDC	1577105	1577104	1577111	1577106	1577110

**Table S2.** Crystallographic details for **3**, **3O**, **3S**, **4** and **5-PF<sub>6</sub>**.


	<b>3</b>	<b>3O</b>	<b>3S</b>	<b>4</b>	<b>5-PF<sub>6</sub></b>
empirical formula	C <sub>45</sub> H <sub>48</sub> BCl <sub>2</sub> IN <sub>6</sub> O P <sub>2</sub> PdW·3 CH <sub>2</sub> Cl <sub>2</sub>	C <sub>45</sub> H <sub>48</sub> BCl <sub>2</sub> IN <sub>6</sub> O <sub>2</sub> P <sub>2</sub> PdW· 2 CH <sub>2</sub> Cl <sub>2</sub>	C <sub>45</sub> H <sub>48</sub> BCl <sub>2</sub> IN <sub>6</sub> O P <sub>2</sub> PdSW· 3 CH <sub>2</sub> Cl <sub>2</sub>	C <sub>39</sub> H <sub>52</sub> Bi <sub>3</sub> N <sub>6</sub> OP <sub>2</sub> PdW· 1.69 CH <sub>2</sub> Cl <sub>2</sub>	C <sub>90</sub> H <sub>96</sub> AuB <sub>2</sub> F <sub>6</sub> I <sub>2</sub> N <sub>12</sub> O <sub>2</sub> P <sub>5</sub> W <sub>2</sub> · 4.25 CH <sub>2</sub> Cl <sub>2</sub>
M <sub>w</sub> / g·mol <sup>-1</sup>	1504.47	1435.54	1536.53	1575.59	2847.29
colour, habit	red, block	green, plate	purple, plate	red, block	brown, plate
crystal system	monoclinic	monoclinic	monoclinic	monoclinic	triclinic
space group	P2 <sub>1</sub> /n	P2 <sub>1</sub> /n	P2 <sub>1</sub> /n	C2/c	P-1
a / Å	15.4833(7)	13.720(5)	18.351(5)	33.3306(10)	10.1419(4)
b / Å	16.6409(7)	19.126(6)	16.067(14)	18.8592(6)	14.2748(5)
c / Å	21.7609(9)	20.619(7)	19.509(5)	19.0257(6)	19.4576(7)
α / °	90	90	90	90	80.163(2)
β / °	91.775(3)	102.678(15)	92.406(12)	112.875(1)	83.571(2)
γ / °	90	90	90	90	77.328(2)
V / Å <sup>3</sup>	5604.1(4)	5279(3)	5747(3)	11018.8(6)	2699.8(2)
Z	4	4	4	8	1
ρ <sub>calcd.</sub> / g·cm <sup>-3</sup>	1.783	1.806	1.776	1.900	1.751
μ / mm <sup>-1</sup>	3.403	3.511	3.355	4.355	4.398
λ <sub>MoKα</sub> / Å	0.71073	0.71073	0.71073	0.71073	0.71073
T / K	123(2)	128(2)	123(2)	123(2)	173(2)
collected refl.	77468	194189	277848	71200	19960
unique refl.	16283	19874	19126	14641	19960
refl. I > 2σ(I)	8894	15927	14952	9183	15608
R <sub>int</sub>	0.0318	0.0797	0.0756	0.0890	0.0497
parameters/restraints	651/21	649/6	654/6	583/16	702/138
R <sub>1</sub> [I > 2σ(I)]	0.0558	0.0405	0.0310	0.0471	0.0354
wR <sub>2</sub> (all data)	0.0990	0.0755	0.0627	0.1077	0.0817
GooF	1.001	1.084	1.040	1.016	1.032
resid. density [eÅ <sup>-3</sup> ]	1.266/-2.360	2.727/-2.145	0.980/-1.490	1.604/-1.715	1.236/-0.938
CCDC	1577102	1577103	1577108	1577109	1577107

### 3. Crystal Structure of 1S




**Figure S1.** Molecular structure of **1S** in the crystal of **1S**·1.5 CH<sub>2</sub>Cl<sub>2</sub> with thermal ellipsoids set at 50% probability. Hydrogen atoms and co-crystallized CH<sub>2</sub>Cl<sub>2</sub> have been omitted for clarity. Major occupation is shown for the disordered alkyne-CO-I ligand set. Selected bond lengths [Å] and angles [°]: W1–I1A 2.7605(3), W1–N1 2.232(2), W1–N3 2.237(2), W1–N5 2.175(2), W1–C1A 2.031(3), W1–C2A 2.045(3), W1–C15A 1.959(4), C1A–C2A 1.312(5), C2A–P1 1.789(3), P1–S1 1.9573(10), P1–C2A–C1A 135.5(2).

### 4. Crystal Structure of 2OO



**Figure S2.** Molecular structure of **2OO** in the crystal of **2OO**·CHCl<sub>3</sub> with thermal ellipsoids set at 50% probability. Hydrogen atoms and co-crystallized CHCl<sub>3</sub> have been omitted for clarity. Major occupation is shown for the disordered iodide/carbonyl ligand set. Selected bond lengths [Å] and angles [°]: W1–I1A 2.7744(3), W1–N1 2.228(3), W1–N3 2.237(2), W1–N5 2.197(3), W1–C1 2.054(3), W1–C2 2.061(3), W1–C3A 1.970(4), C1–C2 1.333(4), C1–P1 1.803(3), C2–P2 1.805(3), P1–O2 1.483(3), P2–O3 1.490(3), P1–C1–C2 135.2(2), C1–C2–P2 138.7(2).


## 5. Crystal Structure of 4



**Figure S3.** Molecular structure of **4** in the crystal of **4**·1.7 CH<sub>2</sub>Cl<sub>2</sub> with thermal ellipsoids set at 50% probability. Hydrogen atoms and co-crystallized CH<sub>2</sub>Cl<sub>2</sub> have been omitted for clarity. Selected bond lengths [Å] and angles [°]: W1–I1 2.7730(6), W1–N1 2.215(6), W1–N3 2.243(5), W1–N5 2.180(5), W1–C1 2.034(7), W1–C2 2.055(6), W1–C3 1.968(8), C1–C2 1.323(8), C1–P1 1.807(7), C2–P2 1.834(6), P1–Pd1 2.259(2), P2–Pd1 2.279(2), Pd1–I2 2.6334(7), Pd1–I3 2.6407(6), P1–C1–C2 118.3(5), C1–C2–P2 120.7(5), I2–Pd1–I3 91.59(2).


## 6. Orbital Interactions in d<sup>4</sup> Alkyne Carbonyl Complexes

The parallel alignment of the alkyne to the carbonyl ligand in d<sup>4</sup> metal complexes can be rationalized by optimized π-interactions between the d<sub>xy</sub>, d<sub>xz</sub> and d<sub>yz</sub> orbitals and the respective ligand orbitals as shown in Figure S4 for Tp\*W(CO)(I)(alkyne).<sup>S1</sup> Only in this arrangement the carbonyl can act as a twofold π-acid (d<sub>yz</sub>→COπ\*<sub>y</sub> and d<sub>xz</sub>→COπ\*<sub>x</sub>) at the same time as the alkyne can act as both π-acid (d<sub>yz</sub>→CCπ\*<sub>||</sub>) and π-base (CCπ\*<sub>||</sub>→d<sub>xy</sub>) retaining its 4e donor character. Independent EHMO calculations by Templeton et al. and Connelly et al. support this rationale even when including any metal halide interactions in the picture.<sup>S2</sup>




**Figure S4.** Schematic representation of important orbital interactions in Tp\*W(CO)(I)(alkyne) and qualitative molecular orbital energies for a parallel alkyne-carbonyl arrangement adapted from reference S1.


## 7. Cyclic Voltammetry



**Figure S5.** Selected cyclic voltammetry of W bisphosalkyne complexes (dashed lines) **2** (black), **2O** (blue), **2S** (green) and their respective PdCl<sub>2</sub> coordination compounds (solid lines) **3** (black), **3O** (blue) and **3S** (green) measured in CH<sub>2</sub>Cl<sub>2</sub> comparing the reversible oxidation waves for the W<sup>II/III</sup> redox process and irreversible reduction of Pd<sup>II</sup>.



**Figure S6.** Selected cyclic voltammetry of bisphosalkyne complexes **2OO** (red) and **2SS** (black).




**Figure S7.** Selected cyclic voltammetry of trinuclear complexe **5**-PF<sub>6</sub>.


\* traces of **2**.

## 8. Stoichiometric Oxidation of $\mathbf{5}\text{-PF}_6$

To a solution of complex  $\mathbf{5}\text{-PF}_6$  (10 mg, 0,004 mmol) in  $\text{CH}_2\text{Cl}_2$  (3 ml) was added a solution of  $\{\text{C}_5\text{H}_4\text{C}(\text{O})\text{CH}_3\}\text{Fe}(\text{C}_5\text{H}_5)\}[\text{PF}_6]^{S3}$  (1,5 mg, 0,004 mmol) in  $\text{CH}_2\text{Cl}_2$  (3 ml) in one portion. The light orange solution turned immediately red. IR spectroscopy (see Figure S8) indicated the formation of mononuclear  $\mathbf{2}^+$  ( $2079\text{ cm}^{-1}$ <sup>S4</sup>) and an unidentified species ( $1960\text{ cm}^{-1}$ ). Further monitoring by IR spectroscopy showed that degeneration started within minutes resulting in regeneration of the starting complex  $\mathbf{5}^+$  ( $1921\text{ cm}^{-1}$ ).  $^{31}\text{P}$  NMR spectroscopy confirmed the identity of  $\mathbf{5}\text{-PF}_6$  but did not allow the identification of other side-products due to their low concentrations. A plausible explanation for the reduction of  $\mathbf{2}^+$  and regeneration of  $\mathbf{5}^+$  is given in Figure S9 postulating the formation of tetranuclear  $[\text{Au}_2(\mathbf{2})_2]^{2+}$  along with  $\mathbf{2}^+$  upon oxidation. Disproportionation of  $\mathbf{2}^+$  and reaction of  $\mathbf{2}$  with  $\text{Au}_2\text{W}_2$  recover 75 % of  $\mathbf{5}\text{-PF}_6$ . However, the fate of the W(IV)-species and one Au(I) equivalent remains unknown. The observation of traces of the redox couple  $\mathbf{2}/\mathbf{2}^+$  already in the cyclic voltammogram (Figure S7) supports the suggested reaction sequence.




**Figure S8.** Selected IR spectra in  $\text{CH}_2\text{Cl}_2$  solution of  $\mathbf{5}\text{-PF}_6$  (black line) and moments after addition of 1 equivalent  $[\text{AcFc}]\text{[PF}_6]$ ,  $\text{AcFc} = \{\text{C}_5\text{H}_4\text{C}(\text{O})\text{CH}_3\}\text{Fe}(\text{C}_5\text{H}_5)$  (red line).




**Figure S9.** Plausible sequence for the oxidation of  $\mathbf{5}\text{-PF}_6$  and subsequent reactions.  $\text{Tp}^* = [(\text{pz}^{\text{Me}_3})_3\text{BH}]^-$


## 9. NMR Spectra




**Figure S10.**  $^1\text{H}$  NMR of **1O** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ .




**Figure S11.**  $^{13}\text{C}$  NMR of **1O** in  $\text{CDCl}_3$  (\*).




**Figure S12.** <sup>31</sup>P NMR of **10** in  $\text{CDCl}_3$ .




**Figure S13.** <sup>1</sup>H NMR of **1S** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , ~ diethyl ether.




**Figure S14.**  $^{13}\text{C}$  NMR of **1S** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , ~ diethyl ether,  $\Phi$  acetone.




**Figure S15.**  $^{31}\text{P}$  NMR of **1S** in  $\text{CDCl}_3$ .




**Figure S16.**  $^1\text{H}$  NMR of **2O** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ .




**Figure S17.**  $^{13}\text{C}$  NMR of **2O** in  $\text{CDCl}_3$  (\*).




**Figure S18.**  $^{31}\text{P}$  NMR of **2O** in  $\text{CDCl}_3$ .




**Figure S19.**  $^1\text{H}$  NMR of **2S** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , ~ diethyl ether, \$ *n*-pentane.




**Figure S20.**  $^{13}\text{C}$  NMR of **2S** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , ~ diethyl ether, \$ *n*\text{-pentane}.




**Figure S21.**  $^{31}\text{P}$  NMR of **2S** in  $\text{CDCl}_3$ .




**Figure S22.**  $^1\text{H}$  NMR of **2OO** in  $\text{CD}_2\text{Cl}_2$  (\*).




**Figure S23.**  $^{13}\text{C}$  NMR of **2OO** in  $\text{CD}_2\text{Cl}_2$  (\*).




**Figure S24.**  $^{31}\text{P}$  NMR of **2OO** in  $\text{CD}_2\text{Cl}_2$ .




**Figure S25.**  $^1\text{H}$  NMR of **2SS** in  $\text{CD}_2\text{Cl}_2$  (\*), #  $\text{CH}_2\text{Cl}_2$ ,  $\Phi$  acetone,  $w$  water.




**Figure S26.**  $^{13}\text{C}$  NMR of **2SS** in  $\text{CD}_2\text{Cl}_2$  (\*),  $\Phi$  acetone.




**Figure S27.**  $^{31}\text{P}$  NMR of **2SS** in  $\text{CD}_2\text{Cl}_2$ .




**Figure S28.**  $^1\text{H}$  NMR of **3** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ .




**Figure S29.**  $^{13}\text{C}$  NMR of **3** in  $\text{CDCl}_3$  (\*).




**Figure S30.** <sup>31</sup>P NMR of **3** in  $\text{CDCl}_3$ .




**Figure S31.** <sup>1</sup>H NMR of **3O** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , § thf.




**Figure S32.**  $^{13}\text{C}$  NMR of **3O** in  $\text{CDCl}_3$  (\*).




**Figure S33.**  $^{31}\text{P}$  NMR of **3O** in  $\text{CDCl}_3$ .




**Figure S34.**  $^1\text{H}$  NMR of **3S** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , § thf, ~ diethyl ether.




**Figure S35.**  $^{13}\text{C}$  NMR of **3S** in  $\text{CDCl}_3$  (\*).




**Figure S36.** <sup>31</sup>P NMR of **3S** in  $\text{CDCl}_3$ .




**Figure S37.** <sup>1</sup>H NMR of **4** in  $\text{CDCl}_3$  (\*), #  $\text{CH}_2\text{Cl}_2$ , ~ diethyl ether.



**Figure S38.** <sup>31</sup>P NMR of **4** in  $\text{CDCl}_3$ .




**Figure S39.** <sup>1</sup>H NMR of **5-PF<sub>6</sub>** in  $\text{CDCl}_3$  (\*), the spectrum quality is determined by solubility limitation.




**Figure S40.**  $^{31}\text{P}$  NMR of **5**- $\text{PF}_6$  in  $\text{CDCl}_3$ , the spectrum quality is determined by solubility limitation.

## 10. DFT Calculations

DFT calculations were carried out as closed shell calculations using the ORCA<sup>55</sup> program package. Molecular geometries of **2**, **2O** and **2OO** were optimized without truncation and symmetry constraints in the gas phase using the BP86 functional.<sup>56</sup> Quasi-relativistic effective core potentials of the Stuttgart/Cologne group were used for W (ECP60) and I (ECP46) in combination with a (8s7p6d2f1g)/[6s5p3d2f1g] basis set for W and a (4s5p)/[2s3p] basis set for I.<sup>57</sup> Split valence triple  $\zeta$ -basis sets (def2-TZVP) of the Ahlrich group were used for the other elements.<sup>58</sup> In doing so a reasonable match between the calculated and the experimentally determined structures was achieved. Frequency calculations were performed to identify all stationary points as minima. The frontier Kohn-Sham orbitals of **2** are depicted with an isosurface value of 0.05 in Figure S41. For the calculations of the 5 lowest vertical singlet singlet transitions of **2**, **2O** and **2OO** TDDFT and the same functional/basis set combination were used. The visible absorption spectra in Figure S42 were obtained by assuming a peak half-width at half height of  $2500\text{ cm}^{-1}$ .



**Figure S41.** Representation of the frontier Kohn-Sham orbitals of **2** (HOMO, LUMO) and associated orbital energy diagram for **2**, **2O** and **2OO**.



**Figure S42.** Calculated visible absorption spectra of **2** ( $\lambda_{\text{max}} = 773 \text{ nm}$ ), **2O** ( $\lambda_{\text{max}} = 807 \text{ nm}$ ) and **2OO** ( $\lambda_{\text{max}} = 833 \text{ nm}$ ).

## **11. References**

- (S1) Frohnapfel, D. S.; Reinartz, S.; White, P. S.; Templeton, J. L. *Organometallics* **1998**, *17*, 3759–3769.
- (S2) (a) Templeton, J. L. *Adv. Organomet. Chem.* **1989**, *29*, 1–100. (b) M. Bartlett, I.; Carlton, S.; G. Connelly, N.; J. Harding, D.; D. Hayward, O.; Guy Orpen, A.; D. Ray, C.; H. Rieger, P. *Chem. Commun.* **1999**, 2403–2404. (c) Adams, C. J.; Bartlett, I. M.; Carlton, S.; Connelly, N. G.; Harding, D. J.; Hayward, O. D.; Orpen, A. G.; Patron, E.; Ray, C. D.; Rieger, P. H. *Dalton Trans.* **2007**, 62–72.
- (S3) Jiao, J.; Long, G. J.; Rebbouh, L.; Grandjean, F.; Beatty, A. M.; Fehlner, T. P. *J. Am. Chem. Soc.* **2005**, *127*, 17819–17831.
- (S4) Helmdach, K.; Ludwig, S.; Villinger, A.; Hollmann, D.; Kösters, J.; Seidel, W. W. *Chem. Commun.* **2017**, *53*, 5894–5897.
- (S5) a) Neese, F. *ORCA – An ab initio, DFT, and semi-empirical SCF-MO package* **2012**, version 3.0.2; b) Neese, F. The ORCA program system, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.* **2012**, *2*, 73–78.
- (S6) a) Becke, A. D. *J. Chem. Phys.* **1986**, *84*, 4524–4529; b) Perdew, J. P. *Phys. Rev. B* **1986**, *33*, 8522.
- (S7) a) Andrae, D.; Häußermann, U.; Dolg, M.; Stoll, H.; Preuß, H. *Theor. Chim. Acta* **1990**, *77*, 123–141; b) Martin, J. M. L.; Sundermann, A. *J. Chem. Phys.* **2001**, *114*, 3408–3420; c) Bergner, A.; Dolg, M.; Küchle, W.; Stoll, H.; Preuß, H. *Mol. Phys.* **1993**, *80*, 1431–1441.
- (S8) Weigend, F.; Ahlrichs, R. *Phys. Chem. Chem. Phys.* **2005**, *7*, 3297–3305.